Cargando…
Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723611/ https://www.ncbi.nlm.nih.gov/pubmed/33313080 http://dx.doi.org/10.21037/atm-20-3440 |
| _version_ | 1783620377273958400 |
|---|---|
| author | Roth, Gael S. Brusset, Bleuenn Decaens, Thomas |
| author_facet | Roth, Gael S. Brusset, Bleuenn Decaens, Thomas |
| author_sort | Roth, Gael S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7723611 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77236112020-12-10 Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line Roth, Gael S. Brusset, Bleuenn Decaens, Thomas Ann Transl Med Editorial Commentary AME Publishing Company 2020-11 /pmc/articles/PMC7723611/ /pubmed/33313080 http://dx.doi.org/10.21037/atm-20-3440 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Roth, Gael S. Brusset, Bleuenn Decaens, Thomas Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title | Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title_full | Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title_fullStr | Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title_full_unstemmed | Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title_short | Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| title_sort | lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723611/ https://www.ncbi.nlm.nih.gov/pubmed/33313080 http://dx.doi.org/10.21037/atm-20-3440 |
| work_keys_str_mv | AT rothgaels lenvatinibinelderlyhepatocellularcarcinomapatientsanewtherapeuticoptioninfirstline AT brussetbleuenn lenvatinibinelderlyhepatocellularcarcinomapatientsanewtherapeuticoptioninfirstline AT decaensthomas lenvatinibinelderlyhepatocellularcarcinomapatientsanewtherapeuticoptioninfirstline |